This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Seeger, K. Articles by Henze, G. Search for Related Content PubMed PubMed Citation Articles by Seeger, K. Articles by Henze, G.

Molecular Quantification of Response to Therapy and Remission Status in TEL-AML1-Positive Childhood ALL by Real-Time Reverse Transcription Polymerase Chain Reaction¹

Department of Pediatric Oncology/Hematology, Otto-Heubner-Centrum [K. S., T. T., D. B., C. E., G. K., G. H.], and Department of Internal Medicine, Hematology/Oncology [K-A. K., U. L., C-A. S.], Charité Medical Center, Campus Virchow, Humboldt-University at Berlin, Berlin, Germany 13353

Although TEL-AML1 positivity [translocation t(12;21)(p13;q22)], detected in 20–25% of initial childhood acute lymphoblastic leukemia (ALL), has been associated with an excellent prognosis, its positive predictive value is insufficient for appropriate treatment stratification considering reported prevalence in relapsed ALL (3–28%). Molecular quantification of response to therapy by PCR-based methods has been shown to improve risk assessment. Here, we report on the sensitive quantification of leukemia-specific TEL-AML1 fusion transcript levels normalized to ß-actin expression (sensitivity threshholds, 10^-5) by a novel real-time reverse transcription-PCR (RQ-RT-PCR) based on fluorescent TaqMan technique providing early and rapid evidence on the treatment efficacy of children with initial or relapsed TEL-AML1⁺ ALL enrolled in frontline or relapse trials of the Berlin-Frankfurt-Münster (BFM)-Study Group. In initial ALL, TEL-AML1/ß-actin decrease was 10⁵-fold in 50% of patients after induction therapy (day 33) and stayed TEL-AML1-negative throughout therapy, which suggested high sensitivity of leukemic cells to antineoplastic therapy. The remaining patients were still TEL-AML1⁺ before reintensification (ratios, 0.7 x 10^-2:10^-4). In relapsed ALL, TEL-AML1/ß-actin decrease was generally less pronounced at corresponding time points, and conversion to TEL-AML1 negativity was observed in 40% of patients. Most notably, subsequent relapses occurred only among molecular poor responders, whereas all early responders remain in their second complete remission. In conclusion, real-time quantification of TEL-AML1/ß-actin kinetics distinguishes distinct molecular response groups, and provides indications capable of directing therapeutic interventions for patients with TEL-AML1⁺ ALL. Before considering modification of therapy, results should be interpreted cautiously taking into account the long duration of remission associated with TEL-AML1⁺ ALL.

This article has been cited by other articles:

				K. Schmidt, K. Seeger, C. Scheibenbogen, R. Bender, M. Abdulla, S. Sussmilch, A. Salama, and A. Moldenhauer Histone deacetylase inhibition improves differentiation of dendritic cells from leukemic blasts of patients with TEL/AML1-positive acute lymphoblastic leukemia J. Leukoc. Biol., March 1, 2009; 85(3): 563 - 573. [Abstract] [Full Text] [PDF]

				A. Moldenhauer, R. C. Frank, J. Pinilla-Ibarz, G. Holland, P. Boccuni, D. A. Scheinberg, A. Salama, K. Seeger, M. A. S. Moore, and S. D. Nimer Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins J. Leukoc. Biol., September 1, 2004; 76(3): 623 - 633. [Abstract] [Full Text] [PDF]

				A. K. Siraj, U. Ozbek, S. Sazawal, S. Sirma, G. Timson, A. Al-Nasser, M. Bhargava, H. El Solh, K. Bhatia, and M. I. Gutierrez Preclinical Validation of a Monochrome Real-Time Multiplex Assay for Translocations in Childhood Acute Lymphoblastic Leukemia Clin. Cancer Res., December 1, 2002; 8(12): 3832 - 3840. [Abstract] [Full Text] [PDF]

				H. Mori, S. M. Colman, Z. Xiao, A. M. Ford, L. E. Healy, C. Donaldson, J. M. Hows, C. Navarrete, and M. Greaves Chromosome translocations and covert leukemic clones are generated during normal fetal development PNAS, June 11, 2002; 99(12): 8242 - 8247. [Abstract] [Full Text] [PDF]